Sebnem Burhan

Sebnem Burhan

Auto-generated profile, based on publicly available information

Sebnem Burhan

Department of Endocrinology and Metabolism, University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2024 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
AHAysa Hacioglu
Aysa Hacioglu
ZKZuleyha karaca
Zuleyha karaca
SUSerhat Uysal
Serhat Uysal
HOHande Mefkure Ozkaya
Hande Mefkure Ozkaya
PKPınar Kadıoğlu
Pınar Kadıoğlu
FKFahrettin Kelestimur
Fahrettin Kelestimur
Objective: Primary hypophysitis might be challenging to diagnose, and there is a lack of evidence regarding optimal treatment strategies due to rarity of the disease. We aim to investigate the clinical features and compare the outcomes of different management strategies of primary hypophysitis in a large group of patients recruited on a nationwide basis. Design: A retrospective observational study. Methods: The demographic, clinical, and radiologic features and follow-up data were collected in study protocol templates and analyzed. Results: One hundred and thirteen patients (78.8% female, median age: 36 years) were included. Lymphocytic (46.7%) and granulomatous hypophysitis (35.6%) were the prevailing subtypes out of 45 patients diagnosed after pathologic investigations. Headache (75.8%) was the most common symptom, and central hypogonadism (49.5%) was the most common hormone insufficiency. Of the patients, 52.2% were clinically observed without interventions, 18.6% were started on glucocorticoid therapy, and 29.2% underwent surgery at presentation. Headache, suprasellar extension, and chiasmal compression were more common among glucocorticoid-treated patients than who were observed. Cox regression analysis revealed higher hormonal and radiologic improvement rates in the glucocorticoid-treated group than observation group (hazard ratio, 4.60; 95% CI, 1.62-12.84 and HR, 3.1; 95% CI, 1.40-6.68, respectively). The main indication for surgery was the inability to exclude a pituitary adenoma in the presence of compression symptoms, with a recurrence rate of 9%. Conclusion: The rate of spontaneous improvement might justify observation in mild cases. Glucocorticoids proved superior to observation in terms of hormonal and radiologic improvements. Surgery may not be curative and might be considered in indeterminate, treatment-resistant, or severe cases.

16 December 2024 in Hormones
Verified
Journal Article
Closed access
PDF file
BEBuruc Erkan
Buruc Erkan
MCMehmet Said Cil
Mehmet Said Cil
MCMehmet Cingoz
Mehmet Cingoz
SBSebnem Burhan
Sebnem Burhan
SASeyma Aksoy
Seyma Aksoy
EHEsra HATIPOGLU
Esra HATIPOGLU

26 February 2026 in Neuroendocrinology
Verified
Journal Article
Closed access
SCSanem Cil
Sanem Cil
APAslihan Pekmezci
Aslihan Pekmezci
HKHüseyin Karatay
Hüseyin Karatay
FDFatih Mert Dogukan
Fatih Mert Dogukan
SBSebnem Burhan
Sebnem Burhan
EHEsra HATIPOGLU
Esra HATIPOGLU
Background: Calcitonin gene-related peptide (CGRP) is a potent vasodilatory neuropeptide involved in inflammation, vascular regulation, and pain mechanisms with potential relevance to endocrine and neurological processes. Furthermore, it exerts specific effects on the tumor microenvironment in certain malignancies. The contribution of CGRP to pituitary adenogenesis has yet to be elucidated. This study aimed to investigate CGRP expression by immunohistochemistry in patients with acromegaly and nonfunctioning pituitary adenomas (NFPAs) and its associations with tumor features, symptoms, and treatment response. Methods: This study included tissue samples obtained from 49 patients who were followed and underwent transsphenoidal surgery at our center: 30 with acromegaly and 19 with NFPAs. Tumor samples were evaluated for CGRP using a polyclonal anti-CGRP antibody (GeneTex, 1:200). Clinical, radiological, and surgical data were collected. Histopathology included hormone staining, estrogen receptor, granularity, transcription factors, Ki-67, and mitotic count. Results: CGRP positivity was observed in 50% of acromegaly patients and in none of the NFPA group (p < 0.001). CGRP expression was not significantly associated with tumor size, invasion, need for surgery, residual tumor, treatment resistance, or granularity. In acromegaly cases with CGRP-positive adenomas, chronic headache tended to be more common (40% vs. 13%, p = 0.09), and postoperative headache resolution rate was lower (33.3% vs. 80%, p = 0.07). The postoperative remission rate tended to be lower (60% vs. 86.7%, p = 0.09). Conclusion: CGRP was found to be notably present in somatotropin-producing adenoma tissues, yet it was entirely absent from nonfunctioning adenoma tissues. The detection of CGRP within adenoma tissue could correlate with an increased incidence of persistent headaches and diminished postoperative remission probabilities in acromegaly.

23 May 2026 in Pituitary
Verified
Journal Article
Open access
PDF file
AYAli Nail Yagci
Ali Nail Yagci
APAslihan Pekmezci
Aslihan Pekmezci
MUMeliha Melin Uygur
Meliha Melin Uygur
SBSebnem Burhan
Sebnem Burhan
MCMelda Celik
Melda Celik
EHEsra HATIPOGLU
Esra HATIPOGLU
Purpose: Pituitary Tumor Centers of Excellence (PTCOE) were developed to standardize multidisciplinary care for pituitary disorders; however, their impact on patient-reported outcomes remains insufficiently characterized. This study aimed to compare health-related quality of life, illness perception, and outpatient satisfaction between patients followed in a PTCOE-aligned, though not formally accredited, specialized pituitary clinic and those managed in general endocrinology clinics, and to identify organizational factors associated with these outcomes. Methods: In this cross-sectional study, 175 adults with prolactinoma ( n = 70), non-functioning pituitary adenoma ( n = 54), acromegaly ( n = 35) and Cushing’s disease ( n = 16) were evaluated across two tertiary endocrinology centers. Patient-reported outcomes were assessed using validated Turkish versions of the SF-36, Illness Perception Scale, and Outpatient Satisfaction Scale. Results: Certain baseline clinical profiles differed significantly between the two groups, with patients in the specialized clinic exhibiting higher rates of pituitary surgery (63.9% vs. 32.1%, p = 0.001) and hypopituitarism (28.9% vs. 14.1%, p = 0.02). Patients in the specialized clinic showed significantly lower SF-36 Role Physical, Role Emotional, Social Functioning, and Bodily Pain scores (all p ≤ 0.03). Illness-perception patterns also diverged, with higher Timeline, Consequences, and Treatment Control scores in the specialized clinic. Outpatient satisfaction, however, was consistently higher across all subscales in the specialized clinic (all p ≤ 0.006). In multivariable analyses, clinic type, sex, hypopituitarism, surgical history, and follow-up duration independently contributed to variation in multiple patient-reported outcome domains. Conclusion: PTCOE-aligned specialized care was associated with more favorable illness representations and higher patient satisfaction, even among cases with greater disease burden. This underscores the need for integrating patient-reported outcomes into the evaluation and refinement of pituitary care models.

1 October 2026 in Experimental Biomedical Research
Verified
Journal Article
Open access
PDF file
SBSebnem Burhan
Sebnem Burhan
MCMuhammed Zeki Cicek
Muhammed Zeki Cicek
Aim: Type 2 diabetes mellitus (T2DM) imposes psychological and behavioral challenges. While prior research links eating habits, distress, and glycemic control, few studies explore these factors together. This study assessed the associations between night eating, eating patterns, diabetes distress (DDS), glycemic control, BMI, gender, and medication use in adults with T2DM. Methods: This study included 105 adults with T2DM. Night eating behavior, eating patterns, and DDS were evaluated using the Night Eating Questionnaire (NEQ), the 18-item version of the Three-Factor Eating Questionnaire-Revised (TFEQ-R18), and the Diabetes Distress Scale (DDS). Results: NEQ score correlated with BMI (r=0.38, p=0.001) and remained significant after adjusting for age, gender, and HbA1c (p=0.002). TFEQ-R18 emotional eating inversely correlated with BMI (r=−0.36, p=0.001) and persisted after adjustment (p=0.004). Uncontrolled eating and cognitive restraint showed no links. Men scored higher on emotional eating than women (10.0 ± 2.54 vs. 8.69 ± 3.20, p = 0.02). Poor glycemic control had higher DDS emotional burden and regimen-related distress; NEQ and TFEQ-R18 scores did not differ by glycemic status or medication classes. Conclusion: DDS, particularly emotional burden and regimen-related distress, differed across HbA1c categories, but this was not confirmed in multivariable models. BMI, not glycemic control, more consistently predicted eating behavior and distress. Given the cross-sectional design and small sample size, the no significant association between eating behavior and glycemic control does not rule out a relationship. These findings support routine distress screening in diabetes care and larger prospective studies of these associations and their relationship to body weight.

19 May 2025 in Bratislava Medical Journal
Verified
Journal Article
Open access
PDF file
BHBurcu Hacioglu
Burcu Hacioglu
SBSebnem Burhan
Sebnem Burhan
HAHilmi Furkan Arslan
Hilmi Furkan Arslan
OBOzlem Balci
Ozlem Balci
AOAysenur Ozderya
Aysenur Ozderya
EHEsra HATIPOGLU
Esra HATIPOGLU
Objective: Acromegaly reduces quality of life. Neurosteroids can impact neuropsychological status and anxiety, but their effects on anxiety in acromegaly cases and quality of life are unclear. This study aims to evaluate the relationship between neurosteroids, anxiety, and quality of life in acromegaly patients. Design: This study included 33 cases in the acromegaly group (AG) and 30 healthy subjects in the control group (CG). Beck Anxiety Inventory (BAI) and Short Form-36 (SF-36) were used to assess anxiety levels and Quality of Life (QoL), respectively. The research assessed how anxiety and quality of life scores correlate with the concentrations of growth hormone, IGF-1, and specific neurosteroids (Allopregnanolone (AP), pregnenolone (PRG), 24S-hydroxycholesterol (24OHC), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), androsterone (ADT)). Results: AG had significantly higher BAI scores in comparison to CG. The SF-36 subdomain scores of general health, physical functioning, role limitations due to physical health, energy/fatigue, emotional well-being, social functioning, and pain were significantly lower in the AG. Conclusion: Neurosteroids may affect the quality of life and be associated with depression and anxiety levels in acromegaly.